- In January 2024, Fresenius Kabi announced the launch of Posaconazole Injection, a generic alternative to Noxafil, for treating or preventing serious fungal infections in adults and children with weakened immune systems. Available in the U.S., this product is the newest addition to Fresenius Kabi’s portfolio, which includes over 30 anti-infective molecules
- In December 2023, Aurobindo Pharma Ltd revealed that its wholly-owned subsidiary, Eugia Pharma Specialities Ltd, received final approval from the U.S. Food and Drug Administration (USFDA) to manufacture and market its generic version of Posaconazole Injection. The approval covers the 300 mg/16.7 mL (18 mg/mL) single-dose vial used for preventing serious fungal infections
- In April 2022, Dr. Reddy’s Laboratories Ltd. and its subsidiaries launched Posaconazole Delayed-Release Tablets, 100 mg, a therapeutic generic equivalent of NOXAFIL (posaconazole) Delayed-Release Tablets, approved by the U.S. Food and Drug Administration (USFDA)
- In February 2021, Lupin Ltd launched its generic equivalent of Noxafil delayed-release tablets, Posaconazole Delayed-Release Tablets, 100 mg. The drug is used for the prevention of invasive aspergillus and candida infections in high-risk patients with compromised immune systems
- In June 2021, Mankind Pharma introduced Posaconazole Gastro-Resistant Tablets under the brand name POSAFORCE 100, indicated for treating mucormycosis patients. The product was also approved by the Drug Controller General of India (DCGI) and recommended by guidelines from AIIMS and ICMR for managing mucormycosis. Posaconazole is a USFDA-approved antifungal drug
